Benefits of duloxetine may outweigh risks in a patient with hormone-positive breast cancer
While emerging evidence suggests venlafaxine may prove an effective alternative, duloxetine remains the agent with the strongest evidence of benefit in patients with CIPN and must remain an option in this patient population.
Authors
- Gustavo Scannapieco Mastroleo
- Kayley Ancy (ORCID: https://orcid.org/0009-0005-3059-3083)
- Akhila Sunkepally Reddy (ORCID: https://orcid.org/0000-0002-7628-8675)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Palliative & Supportive Care
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1017/s1478951525100722
- Citations
- 1
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- University of Texas MD Anderson Cancer Center